Arrowhead gets patent covering new approach to targeted therapeutics

By Elaine Rigoli

Tampa, Fla., April 12 - Arrowhead Research Corp. announced Wednesday that the U.S. Patent Office has issued U.S. Patent 7,018,609, Compositions Containing Inclusion Complexes.

The patent is co-owned by the California Institute of Technology and Arrowhead's majority-owned subsidiary, Insert Therapeutics.

In addition to covering applications pursued by Insert, the technology is licensed for use in RNAi therapeutics to Calando Pharmaceuticals, another majority-owned subsidiary of Arrowhead.

The patent claims cover methods of preparing new therapeutic compositions by assembling drug agents, cyclodextrin-containing polymers and compounds that provide stabilization and targeting abilities, according to a news release.

Headquartered in Pasadena, Calif., Arrowhead is a nanotechnology company structured to commercialize products in a variety of industries, including materials, electronics, life sciences and energy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.